These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 6167418)

  • 21. Inosiplex: an immunomodulation model for the treatment of viral disease.
    Ginsberg T; Glasky AJ
    Ann N Y Acad Sci; 1977 Mar; 284():128-38. PubMed ID: 81634
    [No Abstract]   [Full Text] [Related]  

  • 22. [Therapeutic experiences with the immunostimulator inosine pranobex].
    Darlath W; Wybran J
    Fortschr Med; 1984 Oct; 102(37):932-4. PubMed ID: 6209193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.
    Sliva J; Pantzartzi CN; Votava M
    Adv Ther; 2019 Aug; 36(8):1878-1905. PubMed ID: 31168764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inosine pranobex - cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro].
    Majewska A; Lasek W; Młynarczyk G
    Med Dosw Mikrobiol; 2015; 67(2):107-13. PubMed ID: 26591662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of inosiplex (Isoprinosine) on induced human influenza A infection.
    Khakoo RA; Watson GW; Waldman RH; Ganguly R
    J Antimicrob Chemother; 1981 Apr; 7(4):389-97. PubMed ID: 6166605
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex.
    Dyken PR; Swift A; DuRant RH
    Ann Neurol; 1982 Apr; 11(4):359-64. PubMed ID: 6179455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Isoprinosine--a drug with antiviral and immunomodulating action].
    Deroń Z
    Wiad Lek; 1984 Sep; 37(17):1355-61. PubMed ID: 6084363
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical experiences using the antiviral 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) in Mexico.
    Zertuche HF; Perches RD
    Ann N Y Acad Sci; 1977 Mar; 284():284-8. PubMed ID: 360903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoprinosine: an overview.
    Simon LN; Glasky AJ
    Cancer Treat Rep; 1978 Nov; 62(11):1963-9. PubMed ID: 83189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of inosiplex on viral growth and experimental viral infections (author's transl)].
    Ohnishi H; Kosuzume H; Inaba H; Okura M; Shimada S; Tajima H; Suzuki Y
    Kansenshogaku Zasshi; 1981 Jul; 55(7):490-500. PubMed ID: 6173450
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative studies of inosine pranobex and acyclovir.
    Mindel A
    Am J Med; 1988 Aug; 85(2A):7-9. PubMed ID: 2457315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti SSPE drugs].
    Hosoya M
    Nihon Rinsho; 2012 Apr; 70(4):625-8. PubMed ID: 22568144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levamisole and inosiplex: antiviral agents with immunopotentiating action.
    Hadden JW; Lopez C; O'Reilly RJ; Hadden EM
    Ann N Y Acad Sci; 1977 Mar; 284():139-52. PubMed ID: 81635
    [No Abstract]   [Full Text] [Related]  

  • 34. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.
    Kirsi JJ; North JA; McKernan PA; Murray BK; Canonico PG; Huggins JW; Srivastava PC; Robins RK
    Antimicrob Agents Chemother; 1983 Sep; 24(3):353-61. PubMed ID: 6615611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in antiviral therapy.
    Deeter RG; Khanderia U
    Clin Pharm; 1986 Dec; 5(12):961-76. PubMed ID: 3542344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interferon-inducing and antiviral effects of inosiplex in combination with high-molecular interferon inducers].
    Tazulakhova EB; Amitina NN; Ershov FI
    Biull Eksp Biol Med; 1985 Oct; 100(10):457-9. PubMed ID: 2413924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, virologic, and immunologic effects of combination therapy with ribavirin and isoprinosine in HIV-infected homosexual men.
    Schulof RS; Parenti DM; Simon GL; Paxton H; Meyer WA; Schlesselman SB; Courtless J; LeLacheur S; Sztein MB
    J Acquir Immune Defic Syndr (1988); 1990; 3(5):485-92. PubMed ID: 1691287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro studies on cell-mediated immunity in patients treated with inosiplex for herpes virus infection.
    Bradshaw LJ; Sumner HL
    Ann N Y Acad Sci; 1977 Mar; 284():190-6. PubMed ID: 81637
    [No Abstract]   [Full Text] [Related]  

  • 39. [Protective effects of inosiplex in viral infections. The activity of inosiplex and its constituents (author's transl)].
    Ohnishi H; Kosuzume H; Inaba H; Shimada S; Tajima H; Suzuki Y
    Kansenshogaku Zasshi; 1981 Aug; 55(8):541-50. PubMed ID: 6173451
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical use of antiviral drugs.
    Nahata MC
    Drug Intell Clin Pharm; 1987 May; 21(5):399-405. PubMed ID: 3556126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.